The Evolving Role of NGS and Germline Sequencing in Patients with Advanced and Metastatic Cancer

Experts discuss recent data on next generation sequencing and germline testing in patients with advanced and metastatic cancer.

EP. 1: Defining Germline Sequencing and Incidental Germline Findings

July 22nd 2021

Mark Robson, MD, and a panel of experts discuss key terminology and definitions related to tumor and germline sequencing.

EP. 2: Tumor-Normal Matched Sequencing and Platforms Utilized for Tumor Profiling

July 22nd 2021

Mark Robson, MD, reviews data from a recent abstract on incidental germline findings detected by tumor-normal matched sequencing and the panelists share which platforms they utilize for tumor profiling.

EP. 3: Experience with Interpreting Somatic Reports

July 29th 2021

A panel of experts share their experiences with interpreting information on somatic reports and provide recommendations for verifying results.

EP. 4: Identification of Patients for Germline Testing

July 29th 2021

The panel of experts provide insight on how they identify patients for germline testing.

EP. 5: Role of ctDNA in Germline Testing

August 5th 2021

Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss the evolving role of circulating tumor DNA (ctDNA) in germline testing.

EP. 6: Operational Processes and Challenges

August 5th 2021

Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.